Article

Combination Therapy May Reduce Hepatitis C Treatment Duration

Investigational injectable treatment combined with oral direct-acting antiviral drugs shows results after 8 weeks.

A combinational therapy resulted in a high virologic response rates post-treatment in patients with hepatitis C virus (HCV) genotypes 1 and 4 who did not receive prior treatment.

The phase 2 clinical trial used the investigational injectable treatment RG-101 in combination with oral direct-acting antiviral (DAA) treatment over a 4-week course.

RG-101 works on microRNA-122, which HCV uses to replicate. Drugs that interfere with miR-122 could inhibit replication and act earlier in the viral lifecycle than other approved HCV protease, polymerase, or NS5A inhibitors.

“These early results indicate the potential for RG-101 with oral DAA combination therapy to provide an effective hepatitis C regimen for patients with a short treatment course of just 4 weeks,” said lead study author Mihaly Makara. “We very much hope the long-term, 48-week follow-up data follows the same trend.”

During the study, researchers enrolled 79 HCV genotype 1 or 4 patients who have not received any prior treatment. On day 1, each patient was administered a 2-mg/kg injection of RG-101, followed by a 4 week course of oral DAAs, which included either ledipasvir/sofosbuvir, simeprevir, or daclastasvir followed by a second injection of 2-mg.kg of RG-101 on day 29.

The mean baseline viral load for participants was 5.805 IU/mL.

The interim analysis presented at The International Liver Congress 2016 in Barcelona showed that 97.4% of patients at 8 weeks and 100% of patients at 12 weeks achieved a high virologic response. The high virologic response was determined by using the Abbot RealTimeHCV Assay, which assessed HCV levels below the lower limit of quantification (<12 IU/mL).

The therapy was mostly well tolerated, but there were some mild side effects reported in 11.4% of patients, including headache and fatigue.

“It is encouraging to see a potential treatment combination on the horizon that could limit treatment duration for patients,” said EASL Vice Secretary Tom Hemming Karlsen. “We will be eagerly awaiting the 48 week follow-up data.”

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com